OTS - Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
2022. September 13. 16:00
Lausanne, Switzerland, 13 September, 2022 (APA/OTS) - Debiopharm
Innovation Fund strategically invests in Whitelab Genomics' mission
to make genomic medicine development faster and leaner for more
efficient access to cancer patients in the future
Debiopharm Innovation Fund, the strategic investment arm of
Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com),
announced today their investment in Whitelab Genomics alongside
French Venture Capital company, Omnes Capital, in a $10 Million
Series A Round to advance their mission to accelerate the
development of genomics medicines via technology powered by
artificial intelligence (AI). Whitelab Genomics' computational
platform reduces biotherapies' development time and cost, enabling
faster access to the market and cheaper therapeutic solutions
available for patients in need. Debiopharm's investment in
Whitelabs Genomics contributes to the growth plan of the start-up'
R&D team and US operations. Such an investment aligns with
Debiopharm's focus on investing in digital health solutions that
improve the cancer patient journey, transform pharmaceutical R&D,
and shift healthcare towards a more patient-centric approach.
Founded in 2019 by David Del Bourgo, MBA, and Julien Cottineau,
Ph.D., alongside a team of world-class data scientists specialized
in AI, computational biologists, molecular biologists, and genomic
medicine scientists, the start-up offers in-silico simulations
customized for target discovery, vector, and payload design,
genotoxicity assessment and identification of experimental
protocols of in vitro and in vivo strategies.
"We're moving into a time where AI-based technology will play a
critical role in drug development. With better ways to develop
drugs, de-risk assets, de-risk any toxicity, and ensure efficacy,
we're able to bring more personalized drugs to patients - that's
precisely what Whitelab Genomics is proven to do," stated Tanja
Dowe, CEO of the Debiopharm Innovation Fund.
"The value of using this AI-based platform is the potential
acceleration of pre-clinical, translational stage, helping drug
research companies quickly design payloads and vectors and identify
the best experimental protocols for in vitro and in vivo tests,"
said Hamzeh Abdul-Hadi, Investment Director of the Debiopharm
Innovation Fund.
"We are very excited to close this first institutional
investment round with such renowned investors with deep knowledge
of the pharma environment. With this funding, we can continue
developing our proprietary data sets and algorithms for both
payload and vectors, and develop our collaborations with our
customers," expressed David Del Bourgo, CEO and co-founder of
Whitelab Genomics.
About Whitelab Genomics
WhiteLab Genomics, based in Paris and Cambridge (MA) was
founded in 2019 by David Del Bourgo and Julien Cottineau, experts
in genomics drug development and commercialization. WhiteLab
Genomics aims to revolutionize genomic therapies development using
public and private data and in-house AI algorithms. Whitelab
Genomics supports its clients through the in-silico development
phases enabling them to quickly develop target vectors and payloads
and save precious time needed to give patients access to new
genomic therapies. In only 2 years, Whitelab Genomics has convinced
leading European and US Biotech and pharma to use its solutions for
their new drug development programs, including RNA, DNA & Cell
therapies. WhiteLab Genomics is also collaborating with
world-renowned INSERM and Genethon laboratories and has been
selected by Y-Combinator in its Winter 2022 batch. The company has
won multiple awards, including the Galien Foundation nominee for
startups, the Alumni New Venture Fund from the Polsky Innovation
Center at the University of Chicago, and the Future 40 from Station
F.
For more information, please visit www.whitelabgx.com
About Debiopharm Innovation Fund
Debiopharm Innovation Fund, the strategic investment arm of
Swiss biopharmaceutical company Debiopharm, provides strategic
funding and guidance for companies with an ambition to improve the
patient journey, re-imagine how clinical trials are conducted,
along with companies offering digital platforms that support
cutting-edge drug technologies. Since 2017 Debiopharm has invested
in 14 digital health companies, typically leading the investment
rounds.
For more information, please visit
www.debiopharm.com/digital-health/
We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Bonine
Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.